In the News May 22, 2017

The Pink Sheet | US FDA Urged To Rethink Warning Letters To Avoid 'Collateral Damage'

Cathy Burgess is quoted about the impact that warning letters from the U.S. Food and Drug Administration can have on a manufacturer's operations and reputation.
Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.